Literature DB >> 22274000

Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Xiang Yang Zhang1, Jun Liang, Da Chun Chen, Mei Hong Xiu, Fu De Yang, Therese A Kosten, Thomas R Kosten.   

Abstract

OBJECTIVE: Several lines of evidence suggest that brain-derived neurotrophic factor (BDNF) plays a critical role in activity-dependent neuroplasticity underlying learning and memory in the hippocampus. Schizophrenia has a range of cognitive deficits that may evolve from decreased BDNF, and this study examines this association of BDNF with cognitive deficits in schizophrenia.
MATERIALS AND METHODS: We recruited 251 chronic schizophrenic patients and 206 healthy control subjects and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and serum BDNF in both groups. Schizophrenic symptoms were assessed using the Positive and Negative Syndrome Scale.
RESULTS: BDNF levels were significantly lower in patients than controls (p < 0.001). Cognitive scores on the RBANS and nearly all of its five subscales (all p < 0.001) except for the visuospatial/constructional index (p > 0.05) were significantly lower in schizophrenic patients than normal controls. For the patients, BDNF was positively associated with immediate memory in schizophrenia.
CONCLUSION: Our findings suggest that BDNF may be involved in the pathophysiology of schizophrenia, and its associated cognitive impairment, especially immediate memory.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274000     DOI: 10.1007/s00213-012-2643-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients.

Authors:  Aitor Palomino; Ainara Vallejo-Illarramendi; Ana González-Pinto; Ana Aldama; Cristina González-Gómez; Fernando Mosquera; Gixane González-García; Carlos Matute
Journal:  Schizophr Res       Date:  2006-07-10       Impact factor: 4.939

Review 2.  A review of longitudinal studies of cognitive functions in schizophrenia patients.

Authors:  B R Rund
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

3.  Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.

Authors:  Kazuhiko Toyooka; Koue Asama; Yuichiro Watanabe; Tatsuyuki Muratake; Makoto Takahashi; Toshiyuki Someya; Hiroyuki Nawa
Journal:  Psychiatry Res       Date:  2002-07-31       Impact factor: 3.222

Review 4.  What do we know about neuropsychological aspects of schizophrenia?

Authors:  Barton W Palmer; Sharron E Dawes; Robert K Heaton
Journal:  Neuropsychol Rev       Date:  2009-07-30       Impact factor: 7.444

5.  Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets.

Authors:  Félicien Karege; Michèle Schwald; Mbaye Cisse
Journal:  Neurosci Lett       Date:  2002-08-16       Impact factor: 3.046

6.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

Review 7.  Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

Authors:  Philip D Harvey; Michael F Green; Richard S E Keefe; Dawn I Velligan
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

Review 8.  From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning.

Authors:  William J Tyler; Mariana Alonso; Clive R Bramham; Lucas D Pozzo-Miller
Journal:  Learn Mem       Date:  2002 Sep-Oct       Impact factor: 2.460

9.  Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia.

Authors:  Helton José Reis; Rodrigo Nicolato; Izabela Guimarães Barbosa; Paulo Henrique Teixeira do Prado; Marco Aurélio Romano-Silva; Antonio Lucio Teixeira
Journal:  Neurosci Lett       Date:  2008-05-13       Impact factor: 3.046

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  47 in total

1.  Cognitive profiles and heritability estimates in the Old Order Amish.

Authors:  Ryan M Kuehner; Peter Kochunov; Katie L Nugent; Deanna E Jurius; Anya Savransky; Christopher Gaudiot; Heather A Bruce; James Gold; Alan R Shuldiner; Braxton D Mitchell; L Elliot Hong
Journal:  Psychiatr Genet       Date:  2016-08       Impact factor: 2.458

Review 2.  Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia.

Authors:  Isabel Maurus; Alkomiet Hasan; Astrid Röh; Shun Takahashi; Boris Rauchmann; Daniel Keeser; Berend Malchow; Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-05-21       Impact factor: 5.270

Review 3.  Effects of Intermittent Fasting, Caloric Restriction, and Ramadan Intermittent Fasting on Cognitive Performance at Rest and During Exercise in Adults.

Authors:  Anissa Cherif; Bart Roelands; Romain Meeusen; Karim Chamari
Journal:  Sports Med       Date:  2016-01       Impact factor: 11.136

4.  Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia.

Authors:  Luz H Ospina; Melanie Wall; Lars F Jarskog; Jacob S Ballon; Joseph McEvoy; Matthew N Bartels; Richard Buchsbaum; Richard P Sloan; T Scott Stroup; David Kimhy
Journal:  J Psychiatr Brain Sci       Date:  2019-12-30

5.  Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus.

Authors:  Dan-Dan Zhang; Nan Shi; Hui Fang; Liang Ma; Wei-Ping Wu; Ya-Zhong Zhang; Jin-Li Tian; Luo-Bing Tian; Kang Kang; Si Chen
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

6.  Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits.

Authors:  Julia Vakhrusheva; Brielle Marino; T Scott Stroup; David Kimhy
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-04

Review 7.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

8.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

9.  Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning.

Authors:  David Kimhy; Julia Vakhrusheva; Matthew N Bartels; Hilary F Armstrong; Jacob S Ballon; Samira Khan; Rachel W Chang; Marie C Hansen; Lindsey Ayanruoh; Edward E Smith; Richard P Sloan
Journal:  Psychiatry Res       Date:  2014-09-03       Impact factor: 3.222

10.  Decreased plasma levels of gasotransmitter hydrogen sulfide in patients with schizophrenia: correlation with psychopathology and cognition.

Authors:  Jian-Wen Xiong; Bo Wei; Yan-Kun Li; Jin-Qiong Zhan; Shu-Zhen Jiang; Hai-Bo Chen; Kun Yan; Bin Yu; Yuan-Jian Yang
Journal:  Psychopharmacology (Berl)       Date:  2018-05-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.